ストックスクリーナーアプリを入手
20.00
3.01%
-0.62
前日終値:
$20.62
開ける：
$20.68
24時間の取引高:
120.51K
Relative Volume:
1.20
時価総額：
$1.32B
収益：
-
当期純損益:
$-143.59M
株価収益率:
-7.0832
EPS:
-2.8236
ネットキャッシュフロー:
$-119.47M
1週間 パフォーマンス:
-16.11%
1か月 パフォーマンス:
+17.65%
6か月 パフォーマンス:
+11.11%
1年 パフォーマンス:
+14.94%
1日の値動き範囲:
$19.88
$20.95
1週間の範囲:
$19.70
$23.63
52週間の値動き範囲:
$11.51
$26.33
Pharvaris Nv Stock (PHVS) Company Profile
PHVS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PHVS
Pharvaris Nv
|
20.00 | 1.32B | 0 | -143.59M | -119.47M | -2.8236 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.83 | 120.60B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.63 | 60.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.79 | 42.87B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
595.19 | 36.23B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.51 | 31.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Pharvaris Nv Stock (PHVS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-11 | 開始されました | Guggenheim | Buy |
| 2025-04-29 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-09-25 | 開始されました | Wedbush | Outperform |
| 2023-08-15 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2022-10-05 | 開始されました | Bryan Garnier | Buy |
| 2022-09-13 | 再開されました | JMP Securities | Mkt Outperform |
| 2022-08-23 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-22 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2022-05-25 | 開始されました | JMP Securities | Mkt Outperform |
| 2021-03-02 | 開始されました | BofA Securities | Neutral |
| 2021-03-02 | 開始されました | Morgan Stanley | Overweight |
| 2021-03-02 | 開始されました | Oppenheimer | Outperform |
| 2021-03-02 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Pharvaris Nv (PHVS) 最新ニュース
Volatility clustering patterns for Pharvaris N.V.Trading Watchlist with Real Time Filters - Newser
Combining machine learning predictions for Pharvaris N.V.AI Stock Movement Forecast with Accuracy - Newser
Why is Pharvaris N.V. stock attracting strong analyst attentionFinancial News Planner Backed By Experts - jammulinksnews.com
How to integrate Pharvaris N.V. into portfolio analysis tools Short Term Opportunity Finder with Tools - Newser
How strong is Pharvaris N.V. company’s balance sheetUnlock your trading potential today - jammulinksnews.com
What is the dividend policy of Pharvaris N.V. stockConsistently exceptional gains - jammulinksnews.com
What markets is UKOMW expanding into Is Pharvaris N.V. stock a good long term investment optionInvest confidently with real-time updates - jammulinksnews.com
Is Pharvaris N.V. a growth stock or a value stockCapitalize on emerging investment opportunities - jammulinksnews.com
What is Pharvaris N.V. company’s growth strategyFree Advanced Stock Screener Access - jammulinksnews.com
Pharvaris Announces US$201.2 Million Public Offering of Shares and Pre-Funded Warrants - Global Legal Chronicle
Is Pharvaris N.V. a Top Dividend Stock to Watch in 2025Free Premium Stock Market Reports - Newser
New Product Launches: Will They Boost Pharvaris N.V. Stock in 2025High Probability Setups - Newser
Pharvaris N.V.'s (NASDAQ:PHVS) 11% loss last week hit both individual investors who own 37% as well as institutions - Yahoo.co
Pharvaris N.V. Stock Performance After Earnings: Historical InsightsFree Access to Community - Newser
How Interest Rate Changes Impact Pharvaris N.V. Stock PerformanceElite Investor Club - Newser
How Resilient Is Pharvaris N.V. Stock During Economic DownturnsHigh Return Potential - Newser
What makes Pharvaris N.V. stock price move sharplyPro Trader Stock Focus - metal.it
What analysts say about Pharvaris N.V. stockRecord-setting profit potential - Autocar Professional
Pharvaris' $201.2M Funding: A Strategic Catalyst for HAE Treatment Innovation and Shareholder Value - AInvest
Pharvaris N.V. Stock Analysis and ForecastDynamic investment opportunities - PrintWeekIndia
How Pharvaris N.V. stock performs during market volatilityFree Short-Term Stock Picks - Newser
How Pharvaris N.V. stock reacts to Fed policy changesRapidly growing investment returns - jammulinksnews.com
Pharvaris Raises $201 Million in Successful Offering - TipRanks
Pharvaris Announces Closing of $201.2 Million Upsized Public Offering of Ordinary Shares and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares - The Manila Times
Pharvaris Secures Massive $201M Public Offering: HAE Drug Developer Sees Strong Investor Demand - Stock Titan
Is Pharvaris N.V. a good long term investmentRapid growth opportunities - Autocar Professional
Pharvaris: Deucrictibant Advanced To Target Two Sets Of HAE Patient Populations (PHVS) - Seeking Alpha
What drives Pharvaris N.V. stock priceHigh-yield capital appreciation - jammulinksnews.com
Pharvaris shares slide following $175 million equity offering - MSN
Pharvaris stock drops after pricing $175 million public offering By Investing.com - Investing.com Canada
Pharvaris stock drops after pricing $175 million public offering - Investing.com Australia
Pharvaris' $175M Equity Raise: A Strategic Catalyst for HAE Market Leadership - AInvest
Pharvaris' $175M Equity Raise: Fueling a Strategic Leap in the HAE Market - AInvest
Pharvaris prices $175 million public offering to fund angioedema programs By Investing.com - Investing.com India
Pharvaris Announces Pricing of Upsized $175 Million Public Offering of Ordinary Shares and Pre-Funded Warrants - The Manila Times
Pharvaris prices $175 million public offering to fund angioedema programs - Investing.com
Pharvaris Secures Massive $175M Public Offering to Advance Oral HAE Treatment Pipeline - Stock Titan
Pharvaris Announces Pricing of Upsized $175 Million Public Offering of Ordinary Shares and Pre-Funded Warrants - GlobeNewswire Inc.
Pharvaris Nv (PHVS) 財務データ
収益
当期純利益
現金流量
EPS
1.32%
1.06%
大文字化:
|
ボリューム (24 時間):